About Immunophotonics
Immunophotonics is a private company based in St. Louis, Missouri. It has reported $18,254,544 raised in six offerings on Form D since May 2010. Its chief executive is Robert Arch.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2025 | Sep 4, 2026 | $10,147,612target not set | 45 | $225K | EquityRule 506(b) | Form D ↗ |
| Feb 29, 2024 | Mar 15, 2024 | $1,516,746of $4.0M target | 17 | $89,220 | DebtRule 504, Rule 506(b) | Form D ↗ |
| Jan 6, 2023 | Feb 14, 2023 | $3,452,576of $6.5M target | 22 | $156K | EquityRule 504, Rule 506(b) | Form D ↗ |
| Jun 12, 2014 | Jan 21, 2015 | $2,487,487of $3.3M target | 28 | $88,839 | Equity, Options, Securities on exerciseRule 506(b), 4a5 | Form D ↗ |
| Jun 14, 2011 | Jun 28, 2011 | $100,123of $999K target | 1 | $100K | Equity, Securities on exercise06, 46 | Form D ↗ |
| Apr 27, 2010 | May 12, 2010 | $550,000of $1.0M target | 2 | $275K | Equity, Securities on exercise06, 46 | Form D ↗ |
| Total, six offerings | $18,254,544 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Immunophotonics's Form D filed Sep 4, 2026.
Earlier filings also listed Tomas Hode (executive officer, director and promoter, last listed Mar 2024), Charlie Bolten (director, last listed Mar 2024), Bobby Sandage (director, last listed Mar 2024), Robert Nordquist (director, last listed Jan 2015), Peter Jenkins (director, last listed Jan 2015), Lu Alleruzzo (executive officer, last listed Jan 2015), David Smoller (director, last listed Jan 2015) and Shelly Bishop (director, last listed Jun 2011).
Sources
- SECImmunophotonics, Inc. filing history
- CompanyContact
- CompanyAbout
- PressINJECTABL-1 trial announcement